» Articles » PMID: 34771528

Cell-Cell Fusion Mediated by Viruses and HERV-Derived Fusogens in Cancer Initiation and Progression

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Nov 13
PMID 34771528
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Cell fusion is a well-known, but still scarcely understood biological phenomenon, which might play a role in cancer initiation, progression and formation of metastases. Although the merging of two (cancer) cells appears simple, the entire process is highly complex, energy-dependent and tightly regulated. Among cell fusion-inducing and -regulating factors, so-called fusogens have been identified as a specific type of proteins that are indispensable for overcoming fusion-associated energetic barriers and final merging of plasma membranes. About 8% of the human genome is of retroviral origin and some well-known fusogens, such as syncytin-1, are expressed by human (cancer) cells. Likewise, enveloped viruses can enable and facilitate cell fusion due to evolutionarily optimized fusogens, and are also capable to induce bi- and multinucleation underlining their fusion capacity. Moreover, multinucleated giant cancer cells have been found in tumors derived from oncogenic viruses. Accordingly, a potential correlation between viruses and fusogens of human endogenous retroviral origin in cancer cell fusion will be summarized in this review.

Citing Articles

Fusion of tumor cells and mesenchymal stem/stroma cells: a source of tumor heterogeneity, evolution and recurrence.

Liu Z, Wang Y, Peng Z, Li H, Wang H, Wu Y Med Oncol. 2025; 42(2):52.

PMID: 39838167 DOI: 10.1007/s12032-024-02595-z.


Cell-cell fusion in cancer: The next cancer hallmark?.

Shultes P, Weaver D, Tadele D, Barker-Clarke R, Scott J Int J Biochem Cell Biol. 2024; 175():106649.

PMID: 39186970 PMC: 11752790. DOI: 10.1016/j.biocel.2024.106649.


Exploring the role of endogenous retroviruses in seasonal reproductive cycles: a case study of the ERV-V envelope gene in mink.

Zhang Y, Wang G, Zhu Y, Cao X, Liu F, Li H Front Cell Infect Microbiol. 2024; 14:1404431.

PMID: 39081866 PMC: 11287128. DOI: 10.3389/fcimb.2024.1404431.


How Much Do You Fuse? A Comparison of Cell Fusion Assays in a Breast Cancer Model.

Sieler M, Dornen J, Dittmar T Int J Mol Sci. 2024; 25(11).

PMID: 38891857 PMC: 11172233. DOI: 10.3390/ijms25115668.


Altered Phenotypes of Breast Epithelial × Breast Cancer Hybrids after ZEB1 Knock-Out.

Merckens A, Sieler M, Keil S, Dittmar T Int J Mol Sci. 2023; 24(24).

PMID: 38139138 PMC: 10744253. DOI: 10.3390/ijms242417310.


References
1.
Zhou X, Platt J . Molecular and cellular mechanisms of mammalian cell fusion. Adv Exp Med Biol. 2011; 713:33-64. DOI: 10.1007/978-94-007-0763-4_4. View

2.
Tan L, Jia H, Liu R, Wu J, Han H, Zuo Y . Inhibition of NF-kappaB in fusogenic membrane glycoprotein causing HL-60 cell death: implications for acute myeloid leukemia. Cancer Lett. 2008; 273(1):114-21. DOI: 10.1016/j.canlet.2008.07.035. View

3.
Dittmar T, Zanker K . Cell fusion in health and disease. Volume II: cell fusion in disease. Introduction. Adv Exp Med Biol. 2011; 714:1-3. DOI: 10.1007/978-94-007-0782-5_1. View

4.
Pietropaolo V, Prezioso C, Moens U . Role of Virus-Induced Host Cell Epigenetic Changes in Cancer. Int J Mol Sci. 2021; 22(15). PMC: 8346956. DOI: 10.3390/ijms22158346. View

5.
Bi P, Ramirez-Martinez A, Li H, Cannavino J, McAnally J, Shelton J . Control of muscle formation by the fusogenic micropeptide myomixer. Science. 2017; 356(6335):323-327. PMC: 5502127. DOI: 10.1126/science.aam9361. View